Targeting a diverse spectrum of cancers.

Kinase switch control inhibitors for tumor-targeted and immune-targeted cancer therapies.

Platform

Proficient Life Pharma proprietary switch control platform has generated a diverse clinical pipeline of kinase inhibitor drug candidates including tumor-targeted therapies and immuno-targeted therapies.

Investors

SILV

$38.49

-0.01
09/27/18 4:00 PM EDT
© Nasdaq. Minimum 15 minutes delayed.

Latest News

Sep
25
2018
Proficient Life Pharma to Present at the 2018 Cantor Global Healthcare Conference 
Sep
18
2018
Proficient Life Pharma Appoints Greg C. Martin as Chief Commercial Officer 
Aug
29
2018
Proficient Life Pharma to Participate in Citi’s 13th Annual Biotech Conference